Initial Form 3: Crystal Heter Files as 180 Life Sciences Director, No Securities Reported

Rhea-AI Filing Summary

Crystal Heter filed an initial Form 3 reporting a relationship as a director of 180 Life Sciences Corp. (identified in the filing as ATNF). The event requiring the statement is dated 08/04/2025 and the form is signed 08/12/2025. The filing includes the reporting person's Palo Alto, CA address and explicitly states that no securities are beneficially owned by the reporting person as of the filing. The form is an initial Section 16 filing and contains no entries in the tables for non-derivative or derivative securities.

Positive

• Form 3 was filed and manually signed, meeting the basic Section 16 disclosure requirement
• Reporter identified relationship as Director, providing clarity on role

Negative

• No securities are beneficially owned by the reporting director as stated in the filing

Insights

Corporate Governance Expert

TL;DR: Director filed a Form 3 but reports zero beneficial ownership, indicating no disclosed equity stake at filing.

The filing documents that Crystal Heter is a director of 180 Life Sciences Corp. and that she reported no beneficial ownership of securities in the issuer at the time of this initial statement. From a governance perspective, an initial Form 3 is routine when an individual becomes an officer or director. The absence of reported holdings is notable because it means there is no disclosed equity alignment between this director and shareholders as of the form date. The filing does not disclose any derivatives, options, or indirect interests. Materiality is limited because there are no transactions, grants, or holdings reported.

Securities Compliance Analyst

TL;DR: Compliance filing appears complete and signed; it records no reportable securities or derivative positions.

The Form 3 shows the required items: reporter name and address, relationship to issuer marked as Director, event date 08/04/2025, and a signature dated 08/12/2025. The form explicitly states "No securities are beneficially owned." There are no entries in Table I or Table II, and no amendment indicated. For compliance tracking, this is a straightforward initial statement with no reportable holdings or transactional history to monitor.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Heter Crystal Jane

(Last) (First) (Middle)

3000 EL CAMINO REAL, BLDG. 4

SUITE 200

(Street)

PALO ALTO CA 94306

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/04/2025

3. Issuer Name and Ticker or Trading Symbol
180 Life Sciences Corp. [ ATNF ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Crystal Heter	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Crystal Heter report on Form 3 for 180 Life Sciences Corp. (ATNF)?

The filing reports that Crystal Heter is a director and explicitly states no securities are beneficially owned by her as of the filing.

What is the event date and signature date on the Form 3?

The event requiring the statement is dated 08/04/2025 and the form is signed 08/12/2025.

Does the Form 3 list any derivative or non-derivative securities?

No. The filing contains no entries in Table I (non-derivative securities) or Table II (derivative securities) and states no securities are beneficially owned.

What ticker is shown in the filing for the issuer?

The filing identifies the issuer as 180 Life Sciences Corp. with the trading symbol shown as ATNF in the document.

Where is the reporting person located according to the filing?

The address listed in the filing for Crystal Heter is 3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA 94306.